An Open-Label, Multicenter, Dose-Escalation and Expansion, Phase I Study to Evaluate Safety, Pharmacokinetics, And Anti-Tumor Activity of RO7300490, A Fibroblast Activation Protein-α (FAP) Targeted CD40 Agonist, as Single Agent or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Latest Information Update: 13 Feb 2024
At a glance
- Drugs Atezolizumab (Primary) ; RO 7300490 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 02 Feb 2024 Status changed from recruiting to completed.
- 27 May 2021 Status changed from not yet recruiting to recruiting.
- 29 Apr 2021 New trial record